Combination Antipsychotic May Boost Treatment Persistence
Patients with schizophrenia or bipolar I saw improved medication adherence and fewer hospital visits in a recent analysis.
Updated on Oct. 27, 2026 in Substance Abuse
Live Poll
Do you believe consistent adherence to prescribed medication is the most important factor for managing chronic illness?
Recent data presented at the Academy of Managed Care Pharmacy Nexus meeting suggest that patients with schizophrenia or bipolar I disorder may stay on their medication longer when using olanzapine/samidorphan. These findings highlight differences in treatment persistence and hospital utilization compared to other common antipsychotic therapies.
Why it matters
Maintaining consistency in antipsychotic treatment is a critical factor in reducing the risk of relapse for patients with schizophrenia or bipolar I disorder. This analysis provides new insights into how specific medication choices correlate with healthcare utilization patterns.
A retrospective analysis of pharmacy claims from the Komodo Healthcare Map database compared outcomes for patients taking olanzapine/samidorphan against other antipsychotics over a 12-month period. While the results indicate higher persistence and lower hospital admission rates, the underlying drivers remain under investigation.
The players
Academy of Managed Care Pharmacy
A professional association of pharmacists and clinicians focused on improving patient health through evidence-based medication management.
The details
The analysis tracked adults with schizophrenia and bipolar I disorder, defining treatment persistence as remaining on the initially prescribed medication over 12 months. Discontinuation was characterized by a gap in therapy of at least 45 days. Researchers observed that individuals using the combination therapy showed a mean persistence of 201.8 days, which was linked to reduced frequency of all-cause and disease-related inpatient hospitalizations compared to those using olanzapine alone.
Timeline
October 2020 through December 2024 served as the window for patient prescription data collection.
October 26-29, 2026, marks the dates for the Academy of Managed Care Pharmacy Nexus 2026 meeting.
Health Landscape
This study utilizes the Komodo Healthcare Map database to analyze real-world outcomes for patients on antipsychotic regimens. It reflects an evolving effort in mental health research to move beyond clinical trials and quantify treatment adherence patterns in broad, Medicaid-insured populations.
Adherence to a prescribed antipsychotic regimen is vital for managing schizophrenia and bipolar I disorder. If you or a family member are finding it difficult to stay on a current treatment plan, it is worth discussing with your physician whether a different formulation or approach may offer better stability.
The takeaway
Treatment persistence is a major factor in preventing relapse for those managing schizophrenia and bipolar I disorder. Tracking your own medication schedule and reporting any difficulties with adherence to your psychiatrist can help in identifying barriers to consistent care.
Further reading
For more information on the impact of medication consistency, visit Substance Abuse.
Source note: This article includes information reported by Ajmc.
Live Poll
Do you believe consistent adherence to prescribed medication is the most important factor for managing chronic illness?
